Civica provides vials and syringes of nearly 60 generic sterile injectable medications.


These are the categories of care where Civica products are used:


  • Antibacterial
  • Corticosteroid
  • Pain management
  • Opioid reversal agent
  • Anticholinergic
  • General anesthetic
  • Local anesthetic
  • Antihypertensive
  • Neuromuscular blocker
  • Neuromuscular blocker reversal agent
  • Catecholamine (anti-hypotensive)
For more information about specific medications, visit the FDA's National Drug Code Directory (fda.gov).
  1. In the NDC database for finished drug products, click on Select Type and choose Labeler
  2. In the second field, type Civica
COVID-19 Has Been a Defining Moment for Civica
“Without the ready supply of critical medications from Civica, crucial therapies for our patients could have been compromised during the worst possible time at the epicenter of the pandemic.”
- MARK E. POLLARD, Vice President, Professional Services, NYU Langone

We deliver quality medicines for patients in need.


Civica's purpose is to do what is in the interest of patients. By early 2022, Civica had provided more than 120 million vials/syringes of medications – enough to help treat approximately 50 million patients across the U.S. – and supplied 2.1 million vials to the U.S. Strategic National Stockpile. During the first two years of the COVID-19 pandemic, Civica met up to 400% of the demand for COVID-19 medications, including safety stocks that are part of the Civica model. Eleven Civica medications are used in the treatment of patients with COVID-19.

Civica focuses on quality and price and has secured long-term partnerships with 14 quality suppliers. The majority of Civica's medicines are manufactured in the U.S., Canada and Europe, followed by India. At this time, Civica does not provide any medications with a primary source from China. Civica medicines are labeled with their country of origin and manufacturer.

Civica now and next.


Civica recently announced that it will manufacture three insulins in vial and pen form – glargine (Lantus), lispro (Humalog) and aspart (Novolog) insulin – and sell them at one low, transparent price. The insulins will be manufactured at Civica’s state-of-the-art 140,000 square-foot manufacturing plant, being built in Petersburg, Virginia. The first insulins are expected to be available for purchase in 2024. More information is available at Civicainsulin.org.

Our mission is to make affordable quality medications available to individuals and families when and where they need them.

Click here for news on product updates.